OncoMatch/Clinical Trials/NCT04486352
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Is NCT04486352 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments for endometrial cancer.
Treatment: Atezolizumab - 28 Day Cycle · Bevacizumab · Ipatasertib · Talazoparib · Trastuzumab emtansine · Tiragolumab · Atezolizumab - 21 Day Cycle · Inavolisib · Letrozole · Giredestrant · Abemaciclib — This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Endocrine / hormonal
Cancer type
Endometrial Cancer
Demographics
Prior therapy
Cannot have received: T-cell costimulating or immune checkpoint blockade therapies (CD137 agonists, anti-PD-1, anti-PD-L1, anti-CTLA-4 therapeutic antibodies)
Prior treatment with T-cell costimulating or immune checkpoint blockade therapies including, but not limited to, CD137 agonists, anti-PD-1, anti-PD-L1, and anti-CTLA-4 therapeutic antibodies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- UCSF Helen Diller Family Comprehensive Cancer Center · San Francisco, California
- Medstar Georgetown Cancer Institute · Washington D.C., District of Columbia
- Mount Sinai Comprehensive Cancer Center · Miami Beach, Florida
- University of Chicago · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04486352 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior T-cell costimulating or immune checkpoint blockade therapies disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages